FRI545 Durability Of Treatment Response With VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor, In Patients With Thyroid Eye Disease (TED): Phase 1/2 Clinical Study

por Douglas, Raymond, Ugradar, Shoaib, Cockerham, Kimberley, Eric Turbin, Roger, Tang, Rosa, Nijhawan, Navdeep, O’Shaughnessy, Denis J, Summerfelt, Rochelle M, She, Angela, Katz, Barrett
Publicado 2023

Safety of Intravitreal Gene Therapy for Treatment of Subjects with Leber Hereditary Optic Neuropathy due to Mutations in the Mitochondrial ND4 Gene: The REVEAL Study

por Vignal-Clermont, Catherine, Girmens, Jean-François, Audo, Isabelle, Said, Saddek Mohand, Errera, Marie-Hélène, Plaine, Lise, O’Shaughnessy, Denis, Taiel, Magali, Sahel, José-Alain
Publicado 2021